SubsidieMeestersNovel small molecule attenuator of neuroinflammation in Parkinson’s Disease
NEUROSHIELD aims to develop a novel small molecule targeting neuroinflammation in Parkinson's disease to improve patient quality of life and address a significant treatment gap.
Projectdetails
Introduction
Parkinson’s disease (PD) affects 8.5 million individuals worldwide according to WHO estimates. PD remains cureless and treatments are based on the administration of dopamine precursors or analogues.
Neuroinflammation in Parkinson's Disease
Neuroinflammation is a central hallmark of PD; however, no molecule is present in the market to tackle neuroinflammation in PD patients. Neuroinflammation contributes to the exacerbation of the disease, as the release of inflammatory signals leads to reduced neuronal fitness, driving neuronal death.
NEUROSHIELD's Objective
NEUROSHIELD will address this gap in PD treatment to ensure an increased quality of life for PD patients while exploiting this therapeutic market opportunity.
Limitations of Current Treatments
The use of non-steroidal anti-inflammatory drugs (NSAIDs) in PD has been considered non-effective or raised long-term usage complications due to adverse side effects.
Novel Approach
NEUROSHIELD will employ a novel small molecule tackling neuroinflammation through a yet unexplored pathway, which is a different mechanism from the classic NSAID COX-2 inhibitors.
Discovery of a New Molecule
We have identified a novel potent first-in-class small molecule that is a strong attenuator of neuroinflammation.
Goals of NEUROSHIELD
NEUROSHIELD aims to explore this new safe, brain-permeable molecule, addressing neuroinflammation in Parkinson’s disease through a novel pathway.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-2-2025 |
| Einddatum | 31-7-2026 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- UNIVERSIDADE NOVA DE LISBOApenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
MANUNKIND: Determinants and Dynamics of Collaborative ExploitationThis project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery. | ERC STG | € 1.497.749 | 2022 | Details |
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressureThe UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance. | ERC STG | € 1.498.280 | 2022 | Details |
The Ethics of Loneliness and SociabilityThis project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field. | ERC STG | € 1.025.860 | 2023 | Details |
Uncovering the mechanisms of action of an antiviral bacteriumThis project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function. | ERC STG | € 1.500.000 | 2023 | Details |
MANUNKIND: Determinants and Dynamics of Collaborative Exploitation
This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure
The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.
The Ethics of Loneliness and Sociability
This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.
Uncovering the mechanisms of action of an antiviral bacterium
This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative DiseaseThe project aims to develop a novel human brain-organoid model, called connectoids, to replace animal testing for Parkinson's disease, enhancing therapy monitoring and reducing societal burdens. | EIC Pathfinder | € 2.992.203 | 2022 | Details |
PN6047 - a breakthrough treatment of neuropathic painPharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development. | EIC Accelerator | € 2.493.000 | 2024 | Details |
Revolutionary therapeutic treatment for stopping progression of Parkinson's diseaseHerantis is developing HER-096, a novel pharmaceutical aimed at modifying Parkinson's disease pathology to alleviate symptoms and reduce the societal burden of the condition. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions. | EIC Accelerator | € 1.636.639 | 2024 | Details |
Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative Disease
The project aims to develop a novel human brain-organoid model, called connectoids, to replace animal testing for Parkinson's disease, enhancing therapy monitoring and reducing societal burdens.
PN6047 - a breakthrough treatment of neuropathic pain
PharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development.
Revolutionary therapeutic treatment for stopping progression of Parkinson's disease
Herantis is developing HER-096, a novel pharmaceutical aimed at modifying Parkinson's disease pathology to alleviate symptoms and reduce the societal burden of the condition.
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)
GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions.